Aandelen in “Farmaceutica”

Aandeel Datum Koers Evolutie
vlag Nanobiotix 23/06 36,600 USD
+3,89% 		+3,89%
vlag Nanobiotix 23/06 31,120 EUR
+2,44% 		+2,44%
vlag Nektar Therapeutics 23/06 66,690 USD
+1,51% 		+1,51%
vlag NervGen Pharma Corp 23/06 2,060 USD
-3,74% 		-3,74%
vlag Novartis AG 23/06 153,380 USD
+2,99% 		+2,99%
vlag Novartis AG 23/06 123,420 CHF
+2,61% 		+2,61%
vlag Novo Nordisk A/S 23/06 40,935 EUR
+1,88% 		+1,88%
vlag Novo Nordisk A/S 23/06 47,420 USD
+3,36% 		+3,36%
vlag Nurix Therapeutics Inc 23/06 18,860 USD
+1,13% 		+1,13%

Nieuws over “Farmaceutica”

23/06 · Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients · Persbericht

23/06 · Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients · Persbericht

23/06 · Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT · Persbericht

23/06 · AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection · Persbericht

23/06 · AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis · Persbericht

23/06 · Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia · Persbericht

23/06 · Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses · Persbericht

22/06 · RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement · Persbericht

22/06 · IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026 · Persbericht

22/06 · Lilly declares third-quarter 2026 dividend · Persbericht

22/06 · AbbVie-deal van 11 miljard illustreert de eeuwige race tegen de klok van big pharma · Tijd.be (€)

AbbVie wil via de overname van Apogee Therapeutics potentiële blockbustermedicijnen binnenhalen die binnen een paar jaar zijn huidige sterkhouders moeten aflossen. Dezelfde logica leidde recent ook to...

22/06 · Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer · Persbericht

22/06 · Novo Nordisk A/S - share repurchase programme · Persbericht

22/06 · AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio · Persbericht

22/06 · Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D · Persbericht

22/06 · Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 · Persbericht

19/06 · Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma · Persbericht

18/06 · AbbVie Declares Quarterly Dividend · Persbericht

18/06 · RedHill Biopharma Announces Up To $19.4 Million Private Placement · Persbericht

18/06 · Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery · Persbericht

17/06 · Genprex to Participate at BIO International Convention 2026 · Persbericht

Mijn selecties